Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Unknown authors
Abstract
Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Topics & Concepts
MedicineType 2 diabetesGlucagon-like peptide 1 receptorLiraglutideGlucagon-like peptide-1ReceptorBioinformaticsInternal medicineDiabetes mellitusWorld Wide WebComputer scienceEndocrinologyBiologyAgonistDiabetes Treatment and ManagementNeuroendocrine Tumor Research AdvancesPharmaceutical Practices and Patient Outcomes